期刊文献+

E-cadherin在甲状腺乳头状腺癌中的表达及临床意义 被引量:2

Expression of E-cadherin in papillary thyroid carcinoma and its chlinical significance
下载PDF
导出
摘要 目的 :研究E cadherin在甲状腺乳头状腺癌中的表达 ,并探讨其能否成为甲状腺乳头状腺癌独立的预后因素。方法 :应用免疫组化方法 ,对 40例甲状腺乳头状腺癌、10例甲状腺滤泡型腺瘤和 10例甲状腺正常组织进行了E cadherin表达的研究 ,并对可能影响甲状腺癌病人预后的有关因素进行了时序检验单因素生存分析。结果 :9例 (2 2 5 % )甲状腺乳头状腺癌E cadherin表达阳性 ,余多数呈不表达或弱阳性表达 ,2 0例良性对照均为阳性表达 ,差异有显著性 (P <0 0 5 ) ,17例有淋巴结转移的肿瘤其阳性表达率 (5 9% )明显低于无淋巴结转移的阳性表达率(34 78% ) ,(P <0 0 5 )。经时序检验E cadherin与甲状腺乳头状腺癌病人的预后并未表现出明显的相关关系。结论 :在大多数甲状腺乳头状腺癌中上皮细胞表面的E cadherin有一定的破坏 ,其淋巴结转移的发生与E Purpose:To study the overexpressions of E cadherin and to evaluate whether it can be an independent prognostic factor for patients with papillary thyroid carcinoma. Methods:E cadherin was measured in papillary thyroid carcinomas ( n =40), normal thyroid tissues (n=10),follicular thyroid adenomas(n=10) by immunohistochemical staining. Statistical analysis was based on the Chi squard test and log rank test. Results:We found overexpression of E cadherin in 9 cases (22.5%) among 40 papillary thyroid carcinomas, and E cadherin expression was reduced in the rest of them. Only 1 case had positive expression of E cadherin in the 17 cases with lymph node metastasis. The log rank test for overall survival suggests that E cadherin was not an independent prognostic factor for papillary thyroid carcinoma. Conclusions:E cadherin expression in papillary thyroid carcinoma was reduced, and it was significantly correlated with lymph node metastasis.
出处 《中国癌症杂志》 CAS CSCD 2000年第3期234-236,共3页 China Oncology
关键词 E-CADHERIN 甲状腺乳头状腺癌 免疫组织化学 E-Cadherin papillary thyroid carcinoma
  • 相关文献

参考文献7

  • 1许良中,朱雄增,蒋国梁,杜豫,朱伟萍,张泰明,金爱萍.203例肺癌癌基因与抗癌基因癌蛋白的研究[J].上海医科大学学报,1994,21(4):241-244. 被引量:14
  • 2DykinsR,CobettIP,HerryJA,etal.Longtermsurvivalinbreastcancerrelatedtooverexpressionofthec-erbB-2oncoproteins:animmunohistochemicalstudyusingmonoclonalantibodyNCL-CB11[J].JPathol,1991,163(2):105-110.
  • 3HedingerC,WilliamsED,SobinLH.TheWHOhistologicalclassificationofthyroidtumors:acommentaryonthesecondedition[J].Cancer,1989,63(5):908-911.
  • 4DavisJH.ClinicalSurgery[M],St.Louis,WashingtonDC,Toronto:TheCVMosbyCompany,1987,2555.
  • 5KuniyasuH,EllisLM,EvansDB,etal.RelativeexpressionofE-cadherinandtypeⅣcollagenasegenespredictsdiseaseoutcomeinpatientswithresectablepancreaticcarcinoma[J].ClinCancerRes,1999,5(1):25-33.
  • 6HughTJ,DillonSA,TaylorBA,etal.Cadherincateninexpressioninpriarmycolorectalcancer:asurvivalanalysis[J].BrJCancer,1999,80(7):1046-1051.
  • 7ScheummanGF,HoangVuC,CetinY,etal.ClinicalsignificanceofE-cadherinasaprognosticmarkerinthyroidcarcinomas[J].JClinEndocrianal-Metab,1995,80(7):2168-2172.

二级参考文献1

共引文献13

同被引文献19

  • 1刘阁玲,齐凤英,田金莉,李伟娟,张慧芹,俞芳.血管内皮生长因子、基质金属蛋白酶-9和-E钙粘素在甲状腺癌组织中的表达及意义[J].中国综合临床,2005,21(5):454-456. 被引量:3
  • 2张慧芹,刘阁玲.基质金属蛋白酶-9在甲状腺癌中的表达及临床意义[J].医学理论与实践,2005,18(4):389-390. 被引量:14
  • 3纪柏,王广义,刘亚辉,杨子军.COX-2和VEGF在甲状腺癌中的表达及临床意义[J].中华普通外科杂志,2005,20(11):735-736. 被引量:7
  • 4Natito A,Jwase H,KuzushiaT. Clinical significance of Ecadherin expression in thyroidneoplass[J].Journal of Surgical Oncology,2001,(03):12.
  • 5Spillman MA, Manning NG, Dye WW, et al. Tissue-specific pathways for estrogen regulation of ovarian cancer growth and metastasis [ J ]. Cancer Res ,2010,70 (21) : 8927-8956.
  • 6Mani SA, Guo W, Liao M J, et al. The epithelial-mesenchymal transi- tion generates cells with properties of stem cells[ J]. Ce11,2008,153 (4) :704-715.
  • 7Sabbah M, Emami S, Redeuilh G, et al. Molecular signature and thera- peutic perspective of the epithelial-to-rnesenchymal transitions in epi- thelial cancers[ J]. Drug Resist Updat ,2008,11 (4-5) :123-151.
  • 8Mascarenhas C, Lambe M, BelLocco R, et al. Use of hormone replace- ment therapy before and after ovarian cancer diagnosis and ovarian cancer survival [ J ]. Int J Cancer, 2006,119 ( 12 ) : 2907-2915.
  • 9Moore NL, Hickey TE, Butler LM, et al. Multiple nuclear receptor sig- naling pathways mediate the actions of synthetic progestins in target cells[ J]. Mol Cell Endocrino1,2012,357 ( 1-2 ) :60-70.
  • 10Stanczyk FZ, Hapgood JP, Winer S, et al. Progestogens used in postm- enopausal hormone therapy:differences in their pharmacological prop- erties, intracellular actions, and clinical effects [ J ]. Endocr Rev, 2013,34(2) : 171-208.

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部